~~<i id='9581EC3434'><strike id='9581EC3434'><tt id='9581EC3434'><pre id='9581EC3434'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：hotspot 2025-09-30 12:11:40 - browse：9254

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Astronauts get first look at the spacecraft that will fly them around the moon

entertainment

focus

explore

hotspot

explore

hotspot

Theremovalofsmallamountsofbraintissuefromdesperatelyillpatients,doneaspartofaMountSinairesearchproje

WSS

CDC launches VaccineFinder tool to locate Covid

Software glitch causes Tandem insulin pump to shutdown, FDA warns

CDC launches VaccineFinder tool to locate Covid

Medicare says breakthrough device reimbursement rule to come by summer

How to improve immunocompromised access to mAb treatments

The painfully weak evidence on taking collagen to treat arthritis

knowledge

hotspot

entertainment

Jerome Adams on the need for new antivirals for Covid

Use wet bulb globe temperature, not heat index, to protect workers

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Moonlake's readout produced a cash windfall. Risks remain

Sanofi strikes deal with Novavax, boosting the vaccine maker

Wildfire smoke exposes gaps in outdoor worker protections

Apple Watch's A

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Brain worms: The science behind RFK Jr.'s parasitic infection

focus

Study: AI not yet building 'n

Elevance, private equity launch primary care company

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

‘The Bear’ and hospitality in hospitals

Medicare says breakthrough device reimbursement rule to come by summer

Apple Watch's A

explore

hotspot

explore

hotspot